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tions in BDNF expression levels underlie a variety of psychiatric and neurological
disorders. Indeed, BDNF therapies are currently being investigated in animal models and
clinical studies. However, very little is currently known about the mechanisms that
deregulate BDNF gene expression in these disorders. The BDNF gene structure and tissue
expression pattern is complex, controlled in humans by 9 different gene promoters.
Recently, epigenetic changes at the BDNF gene locus have been proposed to provide a link
between gene and environment. In this review, we will summarize the current knowledge
of BDNF epigenetic regulation with respect to psychiatric disorders and describe how this
information can be applied in therapy and future research.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC
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The neurotrophin family consists of 4 members with impor-
tant functions during nervous system development and
neuronal plasticity. Of these, BDNF has the most abundant
and widespread expression in the mammalian brain (Murer
et al., 1999; Pruunsild et al., 2007). BDNF is released from
neurons both pre- and postsynaptically, either constitutively
or in an activity-dependent manner (Lessmann and
Brigadski, 2009). Secreted BDNF can interact with two recep-
tors: the p75 neurotrophin receptor (p75NTR) and the
tropomyosin-related kinase receptor B (TrkB). Signaling by
BDNF depends on the proteolytical cleavage of a pro-form of
BDNF to a mature form. Whereas proBDNF binds preferen-
tially to p75NTR, mediating apoptosis and long-term depres-
sion, mature BDNF binds to TrkB and stimulates downstream
signaling pathways leading to a plethora of effects: neuronal
differentiation, outgrowth of neurites, increased cell survival
and strengthening of synapses (Barker, 2009; Lu et al., 2005).
Due to its role in neurogenesis and long term potentiation,
BDNF signaling in the limbic structures and cerebral cortex is
central for learning and memory (Cunha et al., 2010).
Disruption of BDNF signaling in the brain, mainly due to
decreases in expression or release, has been linked in recent
years to a range of psychiatric and neurological disorders
(Balaratnasingam and Janca, 2012). A polymorphism in the
coding region for the prodomain of BDNF, called Val66Met, is
associated with memory impairment in humans (Baj et al.,
2013; Egan et al., 2003; Hariri et al., 2003). In vitro studies suggest
that the polymorphism leads to decreased BDNF release (Chen
et al., 2004; Egan et al., 2003). BDNF replacement therapy is
actively being pursued in human and animal models of
diseases, including Huntington's disease, Alzheimer's disease
and depression (Nagahara and Tuszynski, 2011). Furthermore,
antidepressant treatment has been shown to increase levels of
serum BDNF in depressed patients (Dwivedi, 2009).
Due to the central role of BDNF in brain development and
plasticity, early environmental effects on BDNF levels may
have long-term effects on brain activity. Indeed, it is wellTable 1 – Characterization of the human BDNF gene locus.
Exon Promotera CpG islandb ATGa Tissue exp
I Yes Yes Yes Brain and
II Yes Yes Brain only
III Yes Mainly bra
IV Yes CpG-rich Mainly bra
V Yes Mainly bra
Vh Yes Brain and
VI Yes Yes Widesprea
VII Yes Yes Brain only
VIII Yes
VIIIh
IX Yes Yes Widesprea
Vh and VIIIh are speciﬁc to the human BDNF gene.
a Data from Pruunsild et al. (2007).
b Data from Boulle et al. (2012).
c Data from Koppel et al. (2009).
d Data from Pruunsild et al. (2011).known that childhood trauma can lead to psychiatric dis-
orders in adults and that BDNF gene expression is reduced by
acute and chronic stress, as covered by recent reviews
(Balaratnasingam and Janca, 2012; Boulle et al., 2012). The
mechanism leading to BDNF gene down-regulation is, how-
ever, currently unclear. Recent work in rodents suggests an
epigenetic mechanism whereby environmental effects – such
as fear conditioning, electroconvulsive seizure, early-life
adversity and drug treatment – are associated with a change
in Bdnf gene expression (Boulle et al., 2012; Roth and Sweatt,
2011). This review will focus on the human BDNF gene and
highlight research results from recent studies of the epige-
netic regulation of BDNF in human subjects.2. Human BDNF gene regulation
2.1. Complex gene structure and expression
The human BDNF gene locus is complex, consisting of 11
exons and 9 different promoters (Pruunsild et al., 2007)
(Table 1). Additional complexity is present due to alternative
splice sites in exons II and IX, and two alternative polyade-
nylation sites in exon IX. The coding region for mature BDNF
is in exon IX, which is present in all splice forms. Start codons
for translation are present in exons I, VII, VIII and IX, leading
to variations in the N-terminal signal peptide sequence of the
corresponding pre-proBDNF forms. Furthermore, an anti-
sense transcript is synthesized from the opposite DNA strand
and may regulate BDNF transcript levels (Modarresi et al.,
2012; Pruunsild et al., 2007).
Whereas all human BDNF alternative mRNA transcripts are
highly expressed in the brain, some are also expressed in non-
neuronal tissue (Pruunsild et al., 2007). For example, expression
of exon I-containing transcripts is also high in the testis.
Transcripts containing exons Vh, VI and IX have a widespread
expression in peripheral tissues, whereas transcripts containing
exons II, III, IV, V and VII are predominantly brain-speciﬁc
(Table 1). Expression of BDNF transcripts in the human pre-
frontal cortex peaks in the ﬁrst few years of life, consistent withressiona In vivo inductionc In vitro inductiond
testis Highest Highest
in-speciﬁc
in-speciﬁc Highest Highest
in-speciﬁc
few other tissues
d
d Highest
Fig. 1 – Genomic structure of the human BNDF promoters I (A) and IV (B). The positions of CpG dinucleotides are marked with
vertical lines. The 50-most transcriptional start sites (Pruunsild et al., 2007) are marked with an arrow. Cis-acting regulatory
elements (Pruunsild et al., 2011) are indicated below the DNA strand. The positions of the PCR amplicons analyzed in the
following studies are indicated above the DNA strand by the code: D¼D’Addario et al., 2012 and 2013; P¼Perroud et al., 2013;
M¼Mill et al., 2008; Ko¼Kordi-Tamandani et al., 2012; K¼Keller et al., 2010; T¼Tadic et al., 2014; I¼Ikegame et al., 2013b. The
four CpG sites speciﬁcally studied in Keller et al., 2010 are indicated (4CpG).
b r a i n r e s e a r c h 1 5 8 6 ( 2 0 1 4 ) 1 6 2 – 1 7 2164a role in early development (Wong et al., 2009). Generation of
alternative transcripts allows differential regional and subcel-
lular mRNA targeting, as well as promoter-speciﬁc responses to
environmental stimuli (Tongiorgi, 2008).
2.2. Transcriptional regulation
Most of the studies on BDNF gene regulation have been carried
out in rodents, where current evidence suggests that neuronal
activity acts via calcium signaling to stimulate transcription at
Bdnf promoters I and IV (Greer and Greenberg, 2008; West et al.,
2001). Regulation of the human BDNF gene in an in vivo context
has been examined in bacterial artiﬁcial chromosome (BAC)-
transgenic mice (Koppel et al., 2009). This study showed that a
168 kb region spanning the human BDNF locus contains all the
promoter-regulatory elements necessary for tissue-speciﬁc
reporter gene expression. In addition, the human BDNF trans-
gene was inducible by kainic acid, similarly to the endogenous
mouse Bdnf gene. Highest induction levels in both hippocampus
and cortex were observed for human transcripts which had
exons I, IV or IX as the 50-exon (Table 1). This is the ﬁrst
indication that neural activity regulates human BDNF gene
expression in vivo.
A recent study has examined the transcription factors and
cis-elements required for activity-dependent transcription of
the human BDNF gene (Pruunsild et al., 2011). First, it was
demonstrated that KCl stimulation of primary cortical neu-
rons, taken from BAC-transgenic mice with human BDNF
inserted in the genome, led to upregulation of human BDNF
transcripts. Next, rat primary cortical neurons were trans-
fected with human promoter–reporter constructs and sub-
jected to membrane depolarization by treatment with KCl.
In both assays, human promoters I and IV were most upregu-
lated by KCl-depolarization (Table 1). Mutation of a cAMP/
Ca2þ-response element (CRE)-like element in promoter I low-
ered the basal promoter activity but did not affect induction by
KCl. Deletion and mutation analysis identiﬁed an E-box-likebHLH-PAS transcription factor response element (PasRE) in the
proximal promoter region that was sufﬁcient for induction of
the human BDNF promoter I by KCl-depolarization (Fig. 1A).
Furthermore, it was demonstrated that this element bound a
dimer of ARNT2 and NPAS4, two bHLH-PAS transcription
factors, by mobility shift assay, antibody supershift and by
co-transfection with expression plasmids for the native or
dominant-negative ARNT2 and NPAS4 proteins. Based on their
results, the authors suggest that the CRE-like element is
important for basal activity, where NPAS4 levels are limiting.
Neuronal depolarization leads to an increase in NPAS4 levels
and thereby increased ARNT2-NPAS4 heterodimer formation,
leading to increased expression from the exon I promoter. At
the exon IV promoter, the most important cis-regulatory
elements for KCl-mediated induction were determined to be
a CRE, a USF-binding element (UBE) and a PasRE, which bind
CRE-binding protein (CREB), USF and ARNT2-NPAS4, respec-
tively (Fig. 1B). Whereas the CRE element was needed for the
initial transcriptional induction by KCl-depolarization, the
PasRE element was shown to be essential for further enhance-
ment of human BDNF promoter IV induction. Importantly,
chromatin immunoprecipitation studies showed direct bind-
ing of ARNT2 to endogenous human BDNF promoters I and IV,
and CREB to promoter IV, in human postmortem parietal
cortex samples. The importance of neuronal activity-induced
NPAS4 expression in controlling BDNF mRNA expression from
promoters I and IV is supported by rodent studies (Bloodgood
et al., 2013; Lin et al., 2008; Ramamoorthi et al., 2011).3. Epigenetic regulation of BDNF in psychiatric
disorders
3.1. Epigenetics – a link between gene and environment
Discovery of the DNA double helix and the effect of irrever-
sible changes in the DNA sequence, such as point mutations
Fig. 2 – A simpliﬁed model for how reversible epigenetic modiﬁcations regulate transcriptional activity of genes. Acetylated
histones (Ac) are associated with highly active genes, whereas methylation of histones (Me) at speciﬁc lysines (e.g. H3K9 or
H3K27) is an inactivating signal. Methylation of cytosines at CpG dinucleotides in DNA (M) is also inactivating. Epigenetic
modiﬁcations are subject to environmental and genetic effects.
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became obvious that a second layer of gene regulation
existed, as somatic cells display different gene expression
proﬁles despite having the same genetic potential – this layer
was termed “epigenetics”. The modern deﬁnition of epige-
netics is “the study of mitotically and/or meiotically heritable
changes in gene expression not caused by changes in the
DNA sequence” (Feinberg and Tycko, 2004). In recognition of
the widespread usage of the term to describe metastable or
transient changes in chromatin, a recent deﬁnition is based
on the structural adaptation of chromosomal regions, with-
out the requirement for heritability (Bird, 2007).
DNA is wrapped around nucleosomes, which each consist
of 8 histone protein cores that are highly basic. All the
histone proteins can be modiﬁed and the modiﬁcations have
two main mechanisms of action: inﬂuencing the overall
structure of chromatin or regulating the binding of effector
molecules (Bannister and Kouzarides, 2011). One of these
modiﬁcations is histone acetylation, which inﬂuences chro-
matin structure. Histone acetylation is regulated by histone
acetyltransferases (HATs) and histone deacetylases (HDACs).
HATs catalyze the transfer of an acetyl group from acetyl CoA
to the ε-amino group of histone lysine side chains. This
neutralizes the lysine's positive charge and weakens the
interactions between the negative DNA backbone and the
histone, making the DNA more accessible for the transcrip-
tion machinery (Fig. 2). Acetylation is enriched at enhancer
elements and gene promoters, where it is likely to facilitate
access of transcription factors (Wang et al., 2008). HDAC
enzymes remove lysine acetylation, thereby restoring the
positive charge of the lysine and stabilizing local chromatin
architecture. Lysine residues on histones can be methylated
by histone methyltransferases (Fig. 2). The effect of histone
methylation on gene transcription depends on the particular
site of methylation. Methylation of histone H3 at lysine 9
(H3K9) and 27 (H3K27) are normally repressive, via the
recruitment of chromatin-modifying activities such as DNA
methyltransferases (DNMTs) (Cedar and Bergman, 2009). Note
that methylation of histones at other sites (e.g. H3K4) may be
activating, and that bivalent histone methylation marks
exist, e.g. H3K4 and H3K27 trimethylation on poised genepromoters in embryonic stem cells (Bernstein et al., 2006;
Zhou et al., 2011).
DNA methylation correlates with gene repression and is
perhaps the best studied epigenetic mechanism (Bergman
and Cedar, 2013). DNA methylation involves addition of a
methyl group to cytosine and occurs, in mammals, almost
solely in association with CpG dinucleotides. CpG dinucleo-
tides tend to cluster in CpG islands deﬁned as regions of more
than 200 bases that possess a CþG content of minimum 50%
(Portela and Esteller, 2010). Methylated CpG islands are
typically associated with silent DNA whereas unmethylated
CpG islands are targets for transcription factors. About 40–
50% of human genes have CpG islands within or close to their
promoter, the majority of which are unmethylated in normal
cells (Zhu and Yao, 2007).
DNA methylation is carried out by the DNMT family of
enzymes that catalyze the transfer of a methyl group from S-
adenosyl methionine to cytosine in DNA (Fig. 2). Mammals
possess ﬁve DNMT family members: DNMT1, DNMT2,
DNMT3A, DNMT3B and DNMT3L, but only DNMT1, DNMT3A
and DNMT3B have methyltransferase activity (Portela and
Esteller, 2010). The enzymes are categorized into de novo
DNMTs (DNMT3A and DNMT3B) and maintenance DNMTs
(DNMT1). DNMT3A and DNMT3B are considered de novo
enzymes because they are believed to establish the pattern
of methylation during embryonic development and are
highly expressed in embryonic stem cells while downregu-
lated in differentiated cells (Okano et al., 1999). DNMT1 has a
preference for hemi-methylated DNA produced via semi-
conservative replication but also has de novo activity
(Hermann et al., 2004). The mechanism by which transcrip-
tion is repressed after DNA methylation is established is not
entirely clear, but proteins with a methyl‐CpG binding
domain are involved (El-Osta et al., 2001). One such protein,
methyl-CpG-binding protein 2 (MECP2), binds methylated
cytosine and recruits HDAC, leading to transcriptional repres-
sion (Nan et al., 1998). Methylation can also directly inhibit
the access of transcription factors (Kumari and Usdin, 2001).
Gene-speciﬁc demethylation is likely to be directed by
HATs, which in turn are recruited by speciﬁc trans-acting
factors (Bergman and Cedar, 2013). The TET family of
b r a i n r e s e a r c h 1 5 8 6 ( 2 0 1 4 ) 1 6 2 – 1 7 21665-methylcytosine (5 mC) hydroxylases convert 5 mC to
5-hydroxymethylcytosine (5 hmC) as a key initiating step in
active demethylation (Gavin et al., 2013; Guo et al., 2011;
Tahiliani et al., 2009).
Most epigenetic modiﬁcations are believed to be erased
with each generation; however, there have been reports of
changes in DNA methylation that persist in offspring in
mammals (Daxinger and Whitelaw, 2012). Immediately after
fertilization, the paternal genome undergoes rapid DNA
demethylation and histone modiﬁcations, whereas the
maternal genome is gradually demethylated. Eventually,
embryonic methylation is established (Morgan et al., 2005).
On imprinted genes, the pattern of methylation is parent-
speciﬁc, indicating that chromatin marks can survive
embryonic reprogramming (Bergman and Cedar, 2013). Both
environmental and genetic factors affect epigenetic modiﬁca-
tions in the brain, providing a mechanism for gene-
environment interactions in psychiatric disorders (Petronis,
2010; Rutten and Mill, 2009; Tycko, 2010). For example, DNATable 2 – Studies of epigenetic regulation of the BDNF gene in
Test group Variable Epigenetic cha
Schizophrenia, bipolar
disorder and control
subjects
Val66Met SNP Decrease in DN
Schizophrenic patients vs.
healthy controls
Schizophrenia Decrease in DN
Schizophrenic patients vs.
healthy controls
Schizophrenia Increase in DN
speciﬁc CpG
Suicidal vs. non-suicidal
death
Suicidal death Increase in DN
speciﬁc CpG s
Depressed patients vs.
healthy controls
Depression Increase/decre
methylation a
Depressed patients vs.
healthy controls
Depression Increase in DN
Depressed patients Antidepressant
treatment
Decrease in H
trimethylation
Depressed patients Antidepressant
treatment response
Decrease in H
trimethylation
Depressed patients Treatment with
lithium or
valproate
Decrease in DN
Depressed patients Antidepressant
treatment response
Predicted by D
speciﬁc CpG
Depressed patients Suicidal behavior Increase in DN
Bipolar disorder patients vs.
healthy controls
Bipolar disorder Increase in DN
Bipolar disorder II patients
vs. healthy controls
Bipolar disorder II Increase in DN
Bipolar disorder IþII patients Treatment with
lithium or
valproate
Decrease in DN
BPD subjects vs. healthy
controls
Borderline
personality
disorder
Increase in DN
BPD subjects Psychotherapy
response
Decrease in DN
BPD¼borderline personality disorder and NS¼not stated.polymorphisms may alter the ability of a speciﬁc locus to be
epigenetically modiﬁed in response to an environmental
insult (Rutten and Mill, 2009).
3.2. A role for epigenetic regulation of BDNF in psychiatric
disorders?
In recent years, there has been an explosion of interest in
studying BDNF epigenetic regulation in human subjects (see
Table 2). This is partly related to the promising experimental
results from rodent models and initial human postmortem
studies, and partly due to the widespread acceptance that
peripheral blood cells can be used as a proxy for brain tissue
(Boulle et al., 2012; Davies et al., 2012). The ﬁrst paper in
humans, published in 2008, examined DNA methylation in
postmortem brain tissue of major psychosis (schizophrenia
and bipolar disorder) subjects and matched controls
(Mill et al., 2008). There were no signiﬁcant psychosis-
associated methylation differences in exon IX or three otherhuman subjects with relevance for psychiatric disorders.
nges BDNF
promoter
Tissue Reference
A methylation IX
(exonic)
Frontal
cortex
Mill et al. (2008)
A methylation IV Blood
cells
Kordi-
Tamandani
et al. (2012)
A methylation at I Blood
cells
Ikegame et al.
(2013b)
A methylation at
ites
IV Wernicke
area
Keller et al.
(2010)
ase in DNA
t speciﬁc CpG sites
I Blood
cells
Fuchikami
et al. (2011)
A methylation I Blood
cells
D’Addario et al.
(2013)
3K27 IV Frontal
cortex
Chen et al.
(2011)
3K27 IV Blood
cells
Lopez et al.
(2013)
A methylation I Blood
cells
D’Addario et al.
(2013)
NA methylation at IV Blood
cells
Tadic et al.
(2014)
A methylation VI
(exonic)
Blood
cells
Kang et al.
(2013)
A methylation NS Frontal
cortex
Rao et al. (2012)
A methylation I Blood
cells
D’Addario et al.
(2012)
A methylation I Blood
cells
D’Addario et al.
(2012)
A methylation I and IV Blood
cells
Perroud et al.
(2013)
A methylation I and IV Blood
cells
Perroud et al.
(2013)
b r a i n r e s e a r c h 1 5 8 6 ( 2 0 1 4 ) 1 6 2 – 1 7 2 167tested regions (upstream of exons I and VI and immediately
downstream of exon III). However, the authors noted that the
Val66Met SNP in exon IX, which removes a CpG site, is
associated with a decrease in DNA methylation in adjacent
CpG sites, when all tested samples were grouped by geno-
type. Two other papers have examined methylation status in
the peripheral blood cells of schizophrenic patients, com-
pared to healthy controls, with an observed decrease in DNA
methylation in the exon IV promoter (Kordi-Tamandani et al.,
2012) and a modest increase in methylation of a speciﬁc CpG
in the exon I promoter (located at þ11 in Fig. 1A) (Ikegame
et al., 2013b). In the latter study, there was no difference in
DNA methylation at the exon IV promoter.
A key study within this ﬁeld examined BDNF promoter IV
methylation in postmortem brain tissue of suicide comple-
ters (Keller et al., 2010). Importantly, the analyzed gene region
was mainly unmethylated or low methylated in control and
suicide tissue, which is consistent with it being a CpG island.
Using 3 different analysis techniques, four speciﬁc CpG sites
downstream of the transcription start site were identiﬁed
with increased methylation in tissue from suicide victims as
compared to control subjects (Fig. 1B). In 33 controls, the
mean methylation at these 4 CpG sites was always less than
13.0%, whereas in 13 of the 44 suicide victims it was 13.1–
34.2%. Furthermore, in a representative subgroup of samples,
it was shown that BDNF mRNA levels were inversely corre-
lated with the mean degree of methylation at these 4 CpG
sites, suggesting that DNA methylation at these sites may be
involved in transcriptional repression in vivo. Although 70%
of the suicide victims had no psychiatric diagnosis, this study
identiﬁed the region surrounding the BDNF exon IV transcrip-
tion start site as potentially of interest in psychiatric dis-
orders, such as major depression.
DNA methylation at the BDNF exon I and IV promoter
regions were analyzed in peripheral blood cells of depressed
vs. healthy subjects, using a MassARRAY technique
(Fuchikami et al., 2011). Technical difﬁculties reduced the
targeted CpG sites for methylation analysis from 81 to 35
informative CpG sites for exon I, and from 28 to 19 informa-
tive CpG sites for exon IV promoter regions, respectively.
Nonetheless, a methylation proﬁle was identiﬁed for the exon
I promoter, but not for exon IV, in depressed patients that
was distinct from healthy controls. Thus, this study points to
DNA methylation proﬁling at the BDNF exon I promoter as a
potential diagnostic biomarker for major depression. In
another study, methylation of the exon I promoter in blood
cells was shown to be increased in depressed patients,
compared to healthy controls, and was decreased in patients
receiving mood stabilizers in combination with antidepres-
sants, as opposed to antidepressants alone (D’Addario et al.,
2013). Also in blood cells, DNAmethylation status at a speciﬁc
CpG at baseline predicted the ﬁnal response to antidepres-
sant therapy (Tadic et al., 2014). Interestingly, the predictive
CpG lies at 87 in the middle of the PasRE element (Fig. 1B).
Another study in peripheral blood demonstrated that BDNF
methylation status at a CpG island in exon VI was associated
with suicidal behavior in depressed patients (Kang et al.,
2013).
In bipolar disorder, hypermethylation of an unspeciﬁed
BDNF promoter region was observed in postmortem braintissue, compared to healthy controls (Rao et al., 2012).
Analysis of blood cells demonstrated higher levels of DNA
methylation at the exon I promoter in bipolar disorder II,
compared to either healthy controls or bipolar disorder I. In
both bipolar disorder I and II patients, treatment with mood
stabilizers was associated with lower methylation levels
(D’Addario et al., 2012).
Both exon I and IV promoter regions were examined for
DNA methylation in peripheral blood cells from borderline
personality disorder (BPD) subjects and healthy controls.
Higher levels of DNA methylation were observed in both
regions in BPD, compared to healthy controls. In BPD sub-
jects, a decrease in methylation status was observed in
responders to a 4-week psychotherapy course, whereas non-
responders exhibited increased methylation (Perroud et al.,
2013).
A summary of the regions queried for DNA methylation at
BDNF exons I and IV, in selected studies, is presented in Fig. 1.
Three studies used methylation-speciﬁc PCR, which detects
only DNA methylation at the binding sites of the forward and
reverse primers (D’Addario et al., 2012, 2013; Kordi-
Tamandani et al., 2012). One study tested only for methyla-
tion at the methyl-sensitive restriction sites used (Rao et al.,
2012). The overall methylation level in the PCR-ampliﬁed
regions was analyzed in another study (Perroud et al., 2013).
The remaining studies identiﬁed DNA methylation at speciﬁc
CpG sites. It is tempting to speculate that the DNA methyla-
tion changes observed lead to altered binding of general and
sequence-speciﬁc transcription factors to promoters I and IV,
although this awaits further research.
There are few studies examining the role of histone
modiﬁcations at the BDNF gene promoter in humans. In
postmortem brain tissue, the transcriptional up-regulation
of BDNF which occurs from fetal to childhood and/or young
adult stages was shown to be accompanied by increases in
H3K4 trimethylation, a mark of active chromatin, at promo-
ters I and IV (Mellios et al., 2008). In depressed patients, two
studies suggest that antidepressants may regulate BDNF
expression through alterations in the H3K27 methylation
state at promoter IV: In postmortem brain tissue, H3K27
methylation was reduced in patients that had used antide-
pressants, compared to patients free of antidepressants
(Chen et al., 2011). In blood cells, a prospective study in
treatment-naïve depressive subjects revealed a decrease in
H3K27 methylation in responders, but not in non-responders,
after 8 weeks of antidepressant treatment (Lopez et al., 2013).
3.3. Research challenges and limitations
Epigenetics has become a popular topic in psychiatric
research and has the potential to create a bridge in the nature
vs. nurture discussion, but the research is not without
challenges and limitations. One obvious limitation is the fact
that it is not possible to investigate DNA methylation in the
brain tissue of live subjects. For investigations stretching over
time, researchers rely largely on peripheral blood. It is
difﬁcult to conclude to what extent DNA methylation from
blood tissue reﬂects changes in the brain, as blood cells stem
from mesoderm and brain cells originate from ectodermic
tissue. If the environmental factor suspected of inﬂuencing
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as maternal smoking during pregnancy, the use of DNA
methylation in leukocytes as proxy for brain tissue is justi-
ﬁed. However, if the environmental inﬂuence happens after
birth, the changes in DNA methylation are more likely to be
tissue-speciﬁc (Heijmans and Mill, 2012). Alternatively, the
environmental inﬂuence may generate a soluble factor, e.g. a
hormone, which can inﬂuence DNA methylation more
broadly.
Similarity between DNA methylation in whole blood and
regions of the brain was investigated (Davies et al., 2012).
Postmortem brain samples from healthy subject were
obtained together with whole blood samples, taken prior to
death, from a subset of the subjects. The authors discovered
distinct tissue-speciﬁc differences in DNA methylation, espe-
cially in genes involved in neuronal development and differ-
entiation, including an intronic region in BDNF. The tissue-
speciﬁc variation was predominant in intragenic CpG islands,
CpG island shores, and in promoters with low CG density,
whereas CpG islands in promoters were generally hypo-
methylated. Inter-individual differences in DNA methylation
were greatest in blood and lowest in cortex. They did ﬁnd a
correlation between individual DNAmethylation in blood and
brain but as the authors mention, it cannot be excluded that
the individual differences observed are a result of genomic
variation. At the BDNF locus, the Val66Met polymorphism has
been shown to alter DNA methylation, as Val/Val homozy-
gotes have a higher, though modest, DNA methylation level
around the site than individuals with Met (Mill et al., 2008). It
was concluded by Davies et al. (2012) that even though
differences between tissues exceed inter-individual differ-
ences within each tissue, peripheral blood may have some
applicability for studies querying methylation patterns in the
brain. In another study, comparison of the methylation of 8
speciﬁc loci in leukocytes and buccal cells, which are ecto-
dermic of origin, showed similar results in half of the loci
(Talens et al., 2010). This also provides justiﬁcation for the use
of peripheral tissue as proxy for brain DNA methylation, at
least for some loci. One thing that can complicate the
interpretation of DNA methylation in blood is that different
types of leukocytes have slightly different DNA methylation
proﬁles (Heijmans and Mill, 2012). Leukocyte distribution
varies between persons and blood composition is affected
markedly by infection, which can make a blood cell count
necessary. It is then up to the researcher to decide how to
correct for cell count differences or when to exclude subjects.
Another issue is that knowledge regarding DNA methyla-
tion stability is scarce. Flexibility of DNA methylation likely
varies between individual sites and environmental factors
might inﬂuence the ability to rapidly methylate or demethy-
late certain sites. This dynamic regulation is not captured in
postmortem samples but blood samples can potentially
clarify this phenomenon (Lutz and Turecki, 2014). Many
confounders known to alter DNA methylation, e.g. smoking,
diet, and stress, could inﬂuence the results of clinical epige-
netic studies (Philibert et al., 2013; Unternaehrer et al., 2012;
Widiker et al., 2010). In a study designed to measure dynamic
changes in DNAmethylation of the BDNF gene, blood samples
from 76 healthy participants were taken before (pre-stress),
10 min (post-stress), and 90 min after (follow-up) a Triersocial stress test. The target sequence of BDNF was in the 30
region of exon VI, reported to lie within a CpG island that
includes exons V, Vh and VI. Overall DNA methylation of the
BDNF target sequence was found to be stable across the 3
time points, suggesting that psychosocial stress does not
have an acute epigenetic effect on the investigated BDNF
region (Unternaehrer et al., 2012).
In the interpretation of DNA methylation data, it would be
helpful with knowledge about the normal variation of methy-
lation levels for that particular locus. Variation, pattern and
stability of DNA methylation was investigated for 16 candi-
date loci, selected because of potential involvement in cardi-
ovascular and metabolic disease (Talens et al., 2010). The
investigators observed extensive inter-individual variation in
CpG methylation in blood, with the exception of loci that are
either fully methylated or unmethylated. The extent of
variation was different from loci to loci. The authors stress
that DNA methylation should be considered as a quantitative
trait more than just an either/or quality. The high degree of
inter-individual variation in DNA methylation for several loci
is worth remembering when interpreting small differences in
clinical studies.
When investigating epigenetic changes, the researcher has
the difﬁcult task of deciding which genomic location to
investigate. With the complicated gene structure and multiple
promoters of BDNF this is not easy and often earlier studied
regions are selected. Most studies focus on CpG's in promoters
I and IV (Table 2), but intragenic regions may also be important
to investigate. The choice is further complicated by the tissue-
speciﬁc expression pattern that largely depends on promoter
usage. Therefore, investigation of epigenetic changes in one
promoter in leukocytes may not say much about regulation in
the brain. DNA methylation has customarily been studied as
the epigenetic mark, because it is considered relatively stable,
whereas histone modiﬁcations are more transitory (Koﬁnk
et al., 2013). At present, there is a growing acknowledgment
of the dynamic nature of DNAmethylation and that this active
epigenetic ﬂexibility can be important in itself (Baker-
Andresen et al., 2013). Even though histone modiﬁcations
may be just as important to investigate, several things are in
favor of the use of DNA methylation analysis in epigenetic
epidemiology: the amenability to high-throughput analysis
and the possibility of using DNA from whole blood samples
taken by standard procedure for other purposes, which makes
samples more attainable. However, future research is needed
to examine the role of 5 hmC in BDNF epigenetic regulation,
since standard bisulﬁte treatment for detection of methylated
cytosines does not distinguish between 5mC and 5 hmC
(Huang et al., 2010; Jin et al., 2010).
There has been great progress in the technology used to
examine DNA methylation levels with the feasibility of
high-throughput analysis and genome-wide investigation
(Heijmans and Mill, 2012). However, procedures for normal-
ization and quality control have not been standardized and it
is a challenge to compare results from different platforms
where both individual CpG sites as well as groups of CpG's are
measured. In addition, when analyzing loci with intermediate
levels of methylation, different methods can result in
signiﬁcant discrepancies in methylation levels and the choice
of method is often a compromise between coverage and
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epigenetic studies are recommended (Pidsley and Mill, 2011).
The differences in DNA methylation between psychiatric
groups and healthy controls, if present, are often very small
(Table 2). It is unknown whether these very small changes have
any functional effects on transcription. Unfortunately, there are
few studies investigating the effect of epigenetic changes at
speciﬁc sites on gene transcription in human subjects or
in vitro. This has been investigated for BDNF in animal and
cellular models, showing association between the DNA methy-
lation level in promoters I, IV, and VI and gene transcription
(Ikegame et al., 2013a). One study has measured BDNF protein
in blood in order to study gene expression in human subjects
(Perroud et al., 2013). This practice has several challenges as
multiple determinants of blood BDNF level exist. BDNF protein
levels are, for example, highly inﬂuenced by menstrual cycle,
exercise, smoking, and drinking habits (Bus et al., 2011;
Cubeddu et al., 2011). In addition, some methods for the
detection of BDNF levels do not distinguish between BDNF
and proBDNF, which is a problem because proBDNF has an
opposing effect, as it promotes cell death (Lu et al., 2005).
Another issue is that clinical studies may not be hypothesis-
driven in regards to how the transcription level of a certain gene
can affect neural function. The mere existence of epigenetic
changes in a clinical group compared to healthy controls cannot
be used to conclude anything about causality. The epigenetic
changes can very well be secondary to the intake of medication
or disease process, or be caused by confounding factors such as
diet, smoking and socioeconomic factors (Heijmans and Mill,
2012; Philibert et al., 2013; Tehranifar et al., 2013; Widiker et al.,
2010). Investigation of causality is hampered because it is not
possible to carry out longitudinal studies using brain tissue.
Often, sample size is very small, which makes it difﬁcult to
discover discrete differences in epigenetic markers that might
have an effect in transcription. The small samples also hamper
the use of genome-wide analyses that demand bigger samples in
order to gain statistical signiﬁcance. Thus, researchers must
look at speciﬁc regions and this involves the difﬁculties
mentioned above.
Epigenetic changes in psychiatric groups are often investi-
gated by psychologists and psychiatrists that lack understand-
ing of the molecular biological methods used to assess and
interpret DNA methylation results. On the other hand, when
studies are performed by molecular biologists, there may be a
lack of understanding of the diagnostic classiﬁcation and
psychometrics. Furthermore, pressure to publish and high
expectations to the ﬁeld of epigenetics may lead to over-
optimistic interpretation of results. To achieve useful and
correct results in the ﬁeld of psychiatric epigenetics, experi-
enced researchers within both psychiatry and molecular genet-
ics must cooperate and overcome differences in research
methods and terminology. In addition, reviewers and readers
are recommended to be critical about insufﬁcient description of
methods and conclusions which are not substantiated.4. Perspectives for BDNF therapy in psychiatry
Accumulating evidence suggests a role for epigenetics in the
etiology of complex disorders, including psychiatric disorders(Labrie et al., 2012). For example, misregulation of epigenetic
modiﬁcations, also called epimutations, are proposed to
explain the phenotypic discordance seen in monozygotic
twin studies, as well as some de novo cases (Petronis, 2010).
Epimutations may arise from random errors in the main-
tenance of epigenetic marks or by the impact of environ-
mental factors, and is likely to be affected by cis-acting DNA
polymorphisms (Tycko, 2010). Given the importance of BDNF
during brain development and learning, it is perhaps not
surprising that epigenetic changes in this gene have been
sought – and found – in human subjects with schizophrenia,
depression, bipolar disorder and borderline personality dis-
order (Table 2). Although suggestive, demonstration of a
causal role for these epigenetic changes in the etiology of
these psychiatric disorders awaits further study.
In addition to its role as a stable epigenetic modiﬁcation
during early development, DNA methylation is proposed to
be an important mechanism in experience-driven changes in
the brain (Baker-Andresen et al., 2013). The authors suggest
that activity-modiﬁed changes in DNA methylation may not
affect transcription directly, but rather engender structural
changes at the genomic locus that alter the transcriptional
response to future stimuli, e.g. by changing the relative
expression of alternative splice variants. With regards to
the epigenetic regulation of BDNF, direct and indirect effects
of DNA methylation are potential targets of therapy. In order
to reduce non-speciﬁc effects, targeted repair of epigenetic
misregulation may be achieved through use of small inter-
fering RNAs or by sequence-speciﬁc DNA-binding proteins
linked to epigenetic modifying enzymes (Labrie et al., 2012).
Finally, accumulating evidence suggests that epigenetic
mechanisms are involved in the action of antidepressants,
mood stabilizers and psychotherapy at the human BDNF gene
promoter (Table 2). DNA methyltransferase and histone
deacetylase inhibitors, currently being tested in clinical trials
for cancer treatment, could have applications in treating
psychiatric disorders (Boulle et al., 2012; Gavin et al., 2013).
Epigenetic misregulation due to folic acid or vitamin B12
deﬁciency may be amenable to nutritional therapy
(Peedicayil, 2012). Furthermore, epigenetic proﬁling of BDNF
is applicable in both diagnosis and in predicting treatment
response in depressed patients (Fuchikami et al., 2011; Tadic
et al., 2014). Complementary approaches include epigenetic
studies of factors involved either in BDNF signaling, such as
the TrkB receptor itself (Ernst et al., 2009), or in the epigenetic
regulation of BDNF, including MeCP2 (Li and Pozzo-Miller,
2014).5. Conclusion
BDNF has a central role in neuronal development and
neuroplasticity, and its deregulation is implicated in a range
of neurodegenerative and psychiatric disorders. The rapid
pace of research in the epigenetic modiﬁcations and mechan-
isms controlling BDNF gene expression indicates that pro-
gress in BDNF epigenetics will have widespread applicat-
ions in diagnosis, prognosis and biomarkers for psychiatric
disorders.
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